Krystal Biotech (KRYS) Operating Expenses (2016 - 2026)

Krystal Biotech has disclosed Operating Expenses across 11 years of filings, most recently posting $62.7 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $62.7 million, up 20.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $238.7 million (up 6.18% YoY), and the FY2025 annual result was $227.8 million, up 1.36% from the prior year.
• Operating Expenses came in at $62.7 million for Q1 2026 at Krystal Biotech, roughly flat from $62.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $62.8 million in Q4 2025 to a low of $28.8 million in Q2 2022.
• The 5-year median for Operating Expenses is $50.2 million (2022), against an average of $48.3 million.
• Across the five-year window, Operating Expenses jumped 249.91% in 2022 and dropped 8.07% in 2025, its largest moves.
• Krystal Biotech's Operating Expenses stood at $34.8 million in 2022, then grew by 11.86% to $38.9 million in 2023, then grew by 27.94% to $49.8 million in 2024, then gained by 26.27% to $62.8 million in 2025, then decreased by 0.27% to $62.7 million in 2026.
• The last three Operating Expenses figures came in at $62.7 million (Q1 2026), $62.8 million (Q4 2025), and $56.4 million (Q3 2025), per Business Quant data.